FREE Acthar Home Injection Training Services are now available

Licensed nurses are available throughout the country to teach patients how to self-inject Acthar in the privacy of their own home

Requesting Home Injection Training Services for your patient is easy

Step 1

Affix the bright yellow "Home Injection Training Services Requested" sticker to the Acthar referral form.

Your Acthar Specialist will provide the referral forms and stickers, or you can download a referral form now

Step 2

Fax the Acthar referral form as you normally would to the Acthar Support & Access Program (A.S.A.P.) at 1-877-937-2284

Step 3

As soon as Acthar is ready for shipment to the patient from the Specialty Pharmacy, the selected home health agency in the patient's area will contact the patient to set up the injection training visit

Frequently Asked Questions

What qualifications must the nurse meet?

All of the nurses are carefully screened with background checks and investigations of credentials. They must maintain their professional licensing or certification, pass a thorough skills competency program, and participate in ongoing education programs. Additionally, the Acthar Support & Access Program (A.S.A.P.) will send Acthar-specific injection training guides and product information to the patient's home prior to the injection training visit as additional support for the nurse.

Are all injection supplies and equipment provided by the visiting nurse?

No. The patient will receive Acthar and the necessary injection supplies from the Specialty Pharmacy as he/she normally would.

Does insurance pay for Home Injection Training Services?

Home Injection Training Services will be provided free of charge and are made available by support from Questcor, the maker of Acthar.

How quickly will the injection services be scheduled?

Once your patient's prescription of Acthar is ready to ship from the Specialty Pharmacy, the selected home health agency will work to schedule the visit at a time that is most convenient for the patient. Typically, injection training visits are scheduled within 48 hours from the time the patient receives his/her Acthar shipment from the Specialty Pharmacy. Staff from A.S.A.P. will help to guide and expedite this process.

Will the nurse give the patient an actual injection?

No. The visiting nurse will provide direction on how to self-inject Acthar and answer any questions that the patient may have about the injection process, but will not actually perform the injection.

Who can the patient call if he/she has questions?

Acthar patients or care partners can call Acthar Support & Access Program at 1-888-435-2284, Mon-Fri, 8 AM-8 PM ET and ask for assistance with the Acthar Home Injection Training Services.

Questcor

Indications for Use

H.P. Acthar^® Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for:

Monotherapy treatment of infantile spasms (IS) in infants and children under 2 years of age.
The treatment of exacerbations of multiple sclerosis in adults.
For inducing a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.
The following: rheumatic disorders; collagen diseases; dermatologic diseases; allergic states; ophthalmic diseases and respiratory diseases.

Important Safety Information

Acthar should never be given intravenously. It is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency or adrenocortical hyperfunction or sensitivity to proteins of porcine origin. Acthar is contraindicated in children under 2 years of age with suspected congenital infections. Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar.

The adverse effects that may occur with Acthar are related primarily to its steroidogenic effects and are similar to corticosteroids. There may be increased susceptibility to new infection and increased risk of reactivation of latent infections. Adrenal insufficiency may occur after abrupt withdrawal of the drug following prolonged therapy. Cushing’s syndrome, elevated blood pressure, salt and water retention, and hypokalemia may be seen. Masking of symptoms of other underlying disease/disorders may occur. There is a risk of gastrointestinal perforation and bleeding with increased risk of perforation in patients with certain GI disorders. Onset or worsening of euphoria, insomnia, irritability (especially in infants), mood swings, personality changes, depression, and psychosis may occur. Caution should be used when prescribing Acthar to patients with diabetes or myasthenia gravis. Prolonged use may produce cataracts, ocular infections or glaucoma. Use in patients with hypothyroidism or liver cirrhosis may result in an enhanced effect. There may be negative effects on growth and physical development and decreases in bone density.

Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve. Other adverse reactions in adults and children over 2 years of age included: abdominal distension, anxiety, asthma, chest discomfort, congestive heart failure, dizziness, dyspnea, erythema, fatigue, flushing, headache, hyperhidrosis, hypersensitivity or allergic reactions, injection site pain, muscle weakness, palpitations, peripheral edema, tachycardia, and weakness.

This is a summary only. For a full list of warnings, precautions, and adverse events related to Acthar, please refer to the full Prescribing Information including Medication Guide for the treatment of Infantile Spasms.

H.P. Acthar^® Gel and Questcor^® are registered trademarks of Questcor Pharmaceuticals, Inc.

Download the Acthar Referral/Prescription Form

Acthar Support & Access Program

Prescribing Information